Gene Therapy Systems (GTS) Company Profile

06:33 EST 25th November 2017 | BioPortfolio

Gene Therapy Systems, Inc. (GTS) designs, develops and commercializes gene therapy products along with other molecular biological reagents for scientists specializing in gene therapy research. GTS is the only company in the biotechnology reagent business that primarily focuses on gene therapy related products.


10190 Telesis Court
San Diego
United States of America


Phone: (858)-457-1919
Fax: 858-623-9494 or 858-558-3617

News Articles [2644 Associated News Articles listed on BioPortfolio]

[Comment] Gene therapy for -mediated inherited retinal dystrophy completes phase 3

The eye is an attractive organ for gene therapy because of the small amount of tissue that needs to be transfected, surgical accessibility for gene delivery, and the inbuilt control of the second eye....

PBS's Documentary 'The Gene Doctors' Arrives Amid A Gene Therapy Boom

A new PBS film educates viewers about gene therapy at a time when the once controversial field of research is starting to bear fruit.

Britain Backs GSK’s Gene Therapy for ‘Bubble Boy’ Syndrome

(Reuters) – GlaxoSmithKline’s gene therapy for the so-called “bubble boy” disease was approved by Britain’s healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($7...

How Does the New ‘Gene-Altering’ Therapy Fight Cancer? – Live Science

Live ScienceHow Does the New 'Gene-Altering' Therapy Fight Cancer?Live ScienceA new type of cancer treatment that involves altering a person's genes — and could save children's lives — passed a ma...

FDA panel votes in favor of Spark's blindness gene therapy

(Reuters) - Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, ...

British-Finnish Alliance to Bring Gene Therapy to the Masses

FIT Biotech and Avacta hope to combine their technologies to produce highly specific, best-in-class gene therapy treatments. The two companies have spotted an opportunity to bring together their techn...

STAT Plus: Spark Therapeutics’s success is lifting all gene therapy stocks even though risks remain

The stock prices of companies developing gene therapies are surging, so let’s take a moment to remember gene therapy is risky and prone to failure.

Shire’s haemophilia A gene therapy wins Orphan status

Shire’s gene therapy candidate SHP654, an investigational factor VIII (FVIII) gene therapy for the treatment of haemophilia A, has been awarded Orphan Drug Designation by US regulators

PubMed Articles [5629 Associated PubMed Articles listed on BioPortfolio]

Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.

Non-viral polymer-based gene transfer represents an adaptable system for tumor-targeted gene therapy, as various design strategies of shuttle systems together with the mechanistic concept of active tu...

The Tetracycline Responsive System.

Constitutive gene expression is not always the appropriate expression system because the unphysiological levels of expressed protein could be detrimental in studies examining biological roles of prote...

"My Whole Life is Ethics!" Ordinary Ethics and Gene Therapy Clinical Trials.

What and where is ethics in gene therapy? Historical debates have identified a set of ethical issues with the field, and current regulatory systems presume a discrete ethics that can be achieved or pr...

Lipid Nanoparticle Systems for Enabling Gene Therapies.

Genetic drugs such as small interfering RNA (siRNA), mRNA, or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing therapeutic proteins, or t...

Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo.

Class II Transactivator (CIITA) induces transcription of MHC II genes and can potentially be used to improve genetic immunotherapies by converting non-immune cells into cells capable of presenting ant...

Clinical Trials [3897 Associated Clinical Trials listed on BioPortfolio]

Gene Therapy in Treating Patients With Cancer of The Liver

RATIONALE: Inserting the p53 gene into a person's tumor may improve the body's ability to fight liver cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy with the p5...

Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia

OBJECTIVES: I. Develop an approach for treating patients with homozygous familial hypercholesterolemia using gene therapy with autologous hepatocytes transduced with a normal low-density...

Gene Therapy of Beta Thalathemia Using a Self-inactivating Lentiviral Vector

This is a Phase I/II clinical trial of gene transfer for treating Beta-thalassemia using a self-inactivating lentiviral vector to functionally correct the defective gene(s). The objectives...

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in...

Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE...

Companies [2553 Associated Companies listed on BioPortfolio]

Gene Therapy Systems (GTS)

Gene Therapy Systems, Inc. (GTS) designs, develops and commercializes gene therapy products along with other molecular biological reagents for scientists specializing in gene therapy research. GTS is ...

Karolinska Institute

The primary objectives of the European Society of Gene Therapy (ESGT) are to promote basic and clinical research in gene therapy, to promote education and the exchange of information and technology re...

Dimension Therapeutics

Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team compris...


Neurologix, Inc., a leader in the development of innovative therapies for the brain and central nervous system, utilizes gene therapy and other novel technologies. The central nervous system ("CNS") i...


MOLOGEN is specializing in selected areas of Molecular Medicine. Our areas of competence are gene expression, gene therapy and bioinformatics. We are dedicated to the development of DNA expression and...

More Information about "Gene Therapy Systems (GTS)" on BioPortfolio

We have published hundreds of Gene Therapy Systems (GTS) news stories on BioPortfolio along with dozens of Gene Therapy Systems (GTS) Clinical Trials and PubMed Articles about Gene Therapy Systems (GTS) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gene Therapy Systems (GTS) Companies in our database. You can also find out about relevant Gene Therapy Systems (GTS) Drugs and Medications on this site too.

Quick Search

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Corporate Database Quicklinks

Searches Linking to this Company Record